Maravai LifeSciences Holdings, Inc.
MRVI
$3.51
$0.072.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -30.53% | -20.00% | -11.82% | -10.35% | -34.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.53% | -20.00% | -11.82% | -10.35% | -34.03% |
| Cost of Revenue | 2.26% | 2.88% | -0.95% | 1.62% | -10.83% |
| Gross Profit | -68.65% | -47.03% | -25.63% | -23.05% | -49.35% |
| SG&A Expenses | -0.08% | 2.45% | 7.32% | 9.83% | 5.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.67% | 2.54% | 3.24% | 6.01% | -4.44% |
| Operating Income | -187.49% | -132.40% | -91.10% | -200.03% | -156.69% |
| Income Before Tax | -149.56% | -158.32% | -148.71% | -142.40% | 667.56% |
| Income Tax Expenses | -100.55% | -100.50% | -100.26% | -100.25% | 47,572.98% |
| Earnings from Continuing Operations | 33.78% | -105.58% | -81.72% | -87.93% | -648.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.71% | 366.78% | 343.96% | 494.25% | 386.14% |
| Net Income | 46.09% | -43.54% | -24.35% | -21.89% | -1,015.57% |
| EBIT | -187.49% | -132.40% | -91.10% | -200.03% | -156.69% |
| EBITDA | -13,489.97% | -3,158.03% | -931.05% | -255.66% | -99.49% |
| EPS Basic | 48.86% | -33.44% | -16.06% | -14.72% | -983.89% |
| Normalized Basic EPS | -100.58% | -85.05% | -86.98% | -87.57% | 80,818.18% |
| EPS Diluted | 48.86% | -33.31% | -15.94% | -14.59% | -988.64% |
| Normalized Diluted EPS | -100.58% | -85.05% | -86.98% | -87.57% | 80,818.18% |
| Average Basic Shares Outstanding | 5.96% | 7.29% | 6.51% | 4.52% | 2.79% |
| Average Diluted Shares Outstanding | 5.96% | 7.29% | 6.51% | 4.52% | 2.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |